Allogene TherapeuticsALLO
About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Employees: 361
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
153% more call options, than puts
Call options by funds: $446K | Put options by funds: $176K
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
11.26% more ownership
Funds ownership: 78.61% [Q3] → 89.87% (+11.26%) [Q4]
11% more funds holding
Funds holding: 155 [Q3] → 172 (+17) [Q4]
13% less capital invested
Capital invested by funds: $460M [Q3] → $401M (-$59M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Robert Burns 27% 1-year accuracy 46 / 173 met price target | 376%upside $8 | Buy Maintained | 19 Mar 2025 |
Canaccord Genuity John Newman 30% 1-year accuracy 8 / 27 met price target | 733%upside $14 | Buy Maintained | 14 Mar 2025 |
RBC Capital Luca Issi 20% 1-year accuracy 11 / 54 met price target | 495%upside $10 | Outperform Reiterated | 14 Mar 2025 |
Citizens Capital Markets Reni Benjamin 20% 1-year accuracy 8 / 40 met price target | 198%upside $5 | Market Outperform Upgraded | 14 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ALLO published over the past 30 days









